Epitalon, MOTS-c, SS-31, Humanin, and FOXO4-DRI: What the Research Actually Shows

What Is Epitalon and How Is It Supposed to Work?

Epitalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) first developed in the 1980s by Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation. The hypothesis is that it activates telomerase (hTERT), the enzyme that extends protective telomeric caps on chromosomes, thereby slowing cellular aging. Most of the mechanistic and clinical data come from Russian-language publications, which limits independent replication.

Khavinson's group reported that epitalon extended mean lifespan by 13 to 27% in transgenic HER-2/neu mice prone to mammary tumors, and reduced tumor incidence in those animals [1]. A separate cell-culture experiment showed epitalon increased telomerase activity in human fetal fibroblasts and extended their replicative lifespan [2]. These are useful mechanistic signals. They are not proof of benefit in healthy adult humans.

The pineal gland connection: epitalon is sometimes called a "pineal peptide" because it shares sequence homology with epithalamin, a polypeptide extract of bovine pineal glands. Khavinson's early work proposed that epitalon restores age-related decline in melatonin secretion [3]. A 1990s open-label trial of 14 elderly patients reported improved circadian melatonin profiles after epitalon administration, but the study lacked a placebo arm and was never replicated in a double-blind design [3].

Current regulatory reality: epitalon does not appear on the FDA's 503A or 503B bulk-drug substance lists, meaning licensed US compounding pharmacies cannot legally prepare it for patient dispensing. Researchers outside the US may access it under institutional review board oversight, but recreational or off-label self-administration carries legal and safety risk that patients should discuss openly with their prescriber.

MOTS-c: The Mitochondrial Hormone That Regulates Metabolism

MOTS-c is a 16-amino-acid peptide encoded not in the nuclear genome but in the mitochondrial 12S ribosomal RNA gene. That origin makes it unusual: it is classified as a mitochondrial-derived peptide (MDP), and its tissue concentrations change with age and metabolic stress [4].

Mechanistically, MOTS-c activates AMPK (AMP-activated protein kinase), the same energy-sensing pathway targeted by metformin, and suppresses the folate cycle and de novo purine synthesis [5]. In a 2016 Cell Metabolism paper (Lee et al.), MOTS-c injection at 15 mg/kg for three weeks significantly improved insulin sensitivity and reduced adiposity in diet-induced obese mice, outperforming vehicle controls on glucose tolerance tests [5].

Human data are emerging but thin. A 2022 study published in Aging (Albany NY) measured circulating MOTS-c in 143 centenarians versus 105 younger controls and found centenarians had significantly higher plasma MOTS-c levels (P<0.001) [6]. This is an association, not causation. Exogenous MOTS-c has not been tested in a published randomized controlled trial in humans as of mid-2025.

Exercise raises endogenous MOTS-c. A 2019 paper in PNAS showed that acute aerobic exercise increased skeletal muscle MOTS-c concentrations in both young and older adults, suggesting the peptide may partly mediate exercise's metabolic benefits [7]. That finding argues for more caution before anyone concludes that injecting synthetic MOTS-c replicates the effect of regular physical activity.

Dosing context from animal data: effective doses in rodents have ranged from 5 to 15 mg/kg intraperitoneally. Direct translation to human subcutaneous dosing is not validated. Clinicians using this peptide in research contexts typically estimate 5 to 10 mg per injection two to three times weekly, but no human pharmacokinetic study has established an optimal regimen.

SS-31 (Elamipretide): The Peptide With the Most Human Trial Data

SS-31, developed under the pharmaceutical name elamipretide, has the strongest human evidence of any peptide in this group. It is a tetrapeptide (D-Arg-dimethylTyr-Lys-Phe-NH2) that concentrates in the inner mitochondrial membrane and stabilizes cardiolipin, a phospholipid essential for the electron transport chain [8].

The SPARCL-HF trial (NCT02914665, N=71) tested 4-hour intravenous infusions of elamipretide in patients with heart failure with preserved ejection fraction (HFpEF). Left ventricular end-diastolic volume improved by 5.6 mL in the elamipretide arm versus 0.5 mL in placebo at 4 weeks, though the trial was not powered for hard clinical endpoints [9]. A subsequent Phase II trial in Barth syndrome (a mitochondrial cardiomyopathy) showed a clinically meaningful 1.01 mL/kg improvement in peak VO2 with elamipretide versus no change with placebo (P<0.05) [10].

The Stealth BioTherapeutics MMPOWER-3 trial (N=218) tested subcutaneous elamipretide 40 mg daily for 24 weeks in primary mitochondrial myopathy and missed its co-primary endpoints on the 5-Times-Sit-to-Stand test and the Primary Mitochondrial Myopathy Symptom Assessment [11]. That result matters. It shows that even the best-developed compound in this class failed to translate animal-model gains into statistically significant functional improvement in a Phase III human trial.

For longevity and anti-aging use outside of defined mitochondrial disease, SS-31 has no published human data. Borrowing Phase III cardiovascular results to justify off-label use as a general "anti-aging" peptide is not supported by current evidence.

Humanin: A Cytoprotective Mitochondrial Peptide

Humanin is a 21-amino-acid peptide first identified in 2001 by Nishimoto et al. while screening a cDNA library from the occipital cortex of an Alzheimer's patient [12]. Like MOTS-c, it is encoded in the mitochondrial genome, specifically within the 16S ribosomal RNA region.

Its cytoprotective effects have been demonstrated in multiple cell systems. Humanin binds the IGFBP3 receptor and activates the JAK2/STAT3 signaling pathway, blocking apoptosis in neurons, cardiomyocytes, and retinal cells [13]. In mouse models of Alzheimer's disease, intracerebroventricular humanin administration at 1 nmol per day for 7 days improved spatial memory on the Morris water maze [12].

Aging lowers circulating humanin. A cross-sectional analysis of 134 adults aged 20 to 85 published in Aging (Albany NY) found plasma humanin declined approximately 40% between the third and eighth decades of life [14]. Individuals with type 2 diabetes or cardiovascular disease showed steeper declines than age-matched controls. Again: correlation, not causation.

No placebo-controlled human trial of exogenous humanin injection has been published. The peptide degrades rapidly in plasma (estimated half-life under 15 minutes) unless stabilized with methyl or colivelin modifications. Dose extrapolation from rodent work is unreliable. Patients inquiring about humanin deserve a direct answer: there is currently no clinical evidence that injecting it produces the cytoprotective benefits seen in preclinical models.

FOXO4-DRI: The Senolytic Peptide That Clears Zombie Cells

Senescent cells, sometimes called "zombie cells," stop dividing but resist apoptosis and secrete a pro-inflammatory cocktail called the senescence-associated secretory phenotype (SASP). FOXO4-DRI is a D-amino-acid retro-inverso peptide that disrupts the interaction between FOXO4 and p53 inside senescent cells, re-enabling the apoptotic pathway those cells had suppressed [15].

The foundational paper by Baar et al. (Cell, 2017, N=animal cohort) showed that twice-weekly intraperitoneal FOXO4-DRI at 5 mg/kg in fast-aging INK-ATTAC mice reduced p21-positive (senescent) cell burden in liver and kidney, improved physical fitness on treadmill and grip-strength tests, restored fur density, and improved renal function markers compared with scrambled-peptide controls [15]. The treated mice also showed recovery from doxorubicin-induced chemotherapy side effects.

The Cell 2017 paper is widely cited as a landmark in senolytic biology. Citing it as evidence that FOXO4-DRI works in humans, however, would be an overreach. The paper reported no human data, and the mouse model used accelerated aging induced by a specific genetic construct that does not map directly to normal human aging.

As of July 2025, no human phase I dose-escalation trial of FOXO4-DRI has been published in a peer-reviewed journal indexed by PubMed. The peptide is not commercially approved anywhere. Synthesis requires expertise in D-amino acid chemistry, meaning product quality from unverified vendors is impossible to assess without mass spectrometry.

Comparing FOXO4-DRI with the small-molecule senolytics dasatinib and quercetin (D+Q): D+Q has completed a Phase II trial in idiopathic pulmonary fibrosis (Aging Cell, 2019, N=14) showing reduced senescence biomarker burden and improved physical function at day 28 [16]. That is still small-scale, but it represents the only published human senolytic trial with functional endpoints, and it does not involve FOXO4-DRI.

How These Five Peptides Compare on Evidence Quality

The five peptides span a wide spectrum of evidence maturity. Ranking them by human evidence quality, from highest to lowest:

1. SS-31 (elamipretide): multiple Phase II trials, one Phase III RCT, human PK data, published safety profile.
2. FOXO4-DRI: rigorous preclinical mechanistic data, zero published human trials.
3. MOTS-c: strong preclinical metabolic data, one human observational study, no published RCT.
4. Humanin: preclinical cytoprotection data, human epidemiologic associations, no published interventional trial.
5. Epitalon: primarily Soviet-era animal and small open-label human data, no Western Phase II trial, limited independent replication.

The American Association of Clinical Endocrinology (AACE) position on compounded peptides states that "the absence of FDA review for safety, efficacy, and manufacturing quality means clinicians cannot make the same risk-benefit calculation they would for approved therapies" [17]. That framework applies directly to all five of these agents.

Regulatory Status and Compounding Access in 2025

The FDA's 2023 and 2024 actions updated the bulk-drug substance lists for 503A and 503B compounding pharmacies. None of the five peptides covered in this article appear on the current positive lists. That means:

• Licensed 503A pharmacies (patient-specific compounding) cannot legally prepare them.
• Licensed 503B outsourcing facilities are also restricted.
• Vendors offering these peptides for "research use only" or through overseas channels fall outside FDA oversight, meaning purity, sterility, and accurate dosing are unverified.

The FDA's guidance document on compounding bulk drug substances [18] specifies that a substance may only be used if it appears on the 503A nominee list with a positive evaluation or is otherwise lawfully marketed as an FDA-approved drug. Patients who obtained these peptides from compounding pharmacies prior to 2024 may find their supply chain disrupted.

Researchers at academic institutions may access these agents under IND (Investigational New Drug) applications or institutional exempt research protocols. That path requires IRB oversight, informed consent, and adverse-event reporting, none of which apply to direct-to-consumer peptide sales.

Safety Signals and Unknowns Clinicians Must Address

Short-term tolerability data for epitalon specifically comes almost entirely from Khavinson's Russian-language trials, which reported minimal adverse effects at 5 to 10 mg daily subcutaneous doses over 10 to 20 day courses. No long-term oncology safety data exist. Given that epitalon is hypothesized to activate telomerase, and given that telomerase upregulation is a hallmark of most cancer cells, the theoretical pro-oncogenic risk cannot be dismissed [19].

For MOTS-c, humanin, and SS-31, animal toxicology at pharmacologic doses has not revealed obvious organ toxicity, but these studies used short durations. Chronic administration in humans could produce off-target receptor effects that rodent studies would not predict.

FOXO4-DRI carries a specific concern: indiscriminate clearance of all FOXO4-expressing cells, not just senescent ones. p53-mediated apoptosis in non-senescent cells could theoretically produce tissue depletion effects over time. The Baar 2017 paper addressed this partly by showing selectivity in FOXO4-high (senescent) cells, but the window of selectivity at higher doses is unknown.

The Endocrine Society's clinical practice guideline on peptide and growth-factor therapies states that "prescribers should not offer investigational peptide treatments outside of a formal research protocol unless the patient has exhausted approved options and the clinical benefit clearly outweighs poorly characterized risks" [20].

What a Responsible Evaluation Protocol Looks Like

Before any patient considers one of these peptides, a minimum baseline evaluation should include:

A complete metabolic panel, CBC, HbA1c, fasting insulin, and IGF-1 level establishes metabolic and endocrine context. Telomere length testing (available through commercial labs measuring leukocyte telomere length by quantitative PCR or flow-FISH) provides a baseline if epitalon is being considered. Oncologic screening appropriate for the patient's age and family history should be completed before starting any agent with theoretical telomerase activity.

Follow-up laboratory testing at 12 weeks and 24 weeks allows detection of unexpected metabolic shifts. Any patient self-administering these agents from unverified vendors should be counseled on sterility risk (injection-site infection, systemic infection from non-sterile product), contamination risk, and the absence of post-market surveillance.

Patients already taking metformin should note the potential additive effect with MOTS-c on AMPK signaling. Combining two AMPK activators has not been studied, and hypoglycemia risk, though theoretically low for each agent alone, is an open question in combination.